E

Elekta

Delivers precision radiation therapy equipment

Principal Software Engineer - Shared Components

Full-Time
No salary listed
Expert
Crawley, UK
HybridFour days on-site at the Crawley headquarters and one day working from home each week.
Software EngineeringBackend Engineering

About the job

Requirements
  • Extensive software engineering experience with a strong background in C#, .NET, ASP.NET Core, and distributed systems.
  • Experience designing reusable services, versioned application programming interfaces, microservices, and event-driven architectures.
  • Strong experience with Docker, Kubernetes, Helm, cloud-native technologies, and modern deployment practices.
  • Knowledge of continuous integration and continuous delivery, automated testing, and development tools such as Azure DevOps or Jenkins.
  • Experience leading technical initiatives, influencing architecture decisions, and mentoring engineers.
  • Strong problem-solving skills with the ability to balance technical quality, delivery priorities, and risk.
Responsibilities
  • Lead the design, development, and maintenance of shared software components and services using C# and .NET for cloud and on-premises deployments.
  • Define application programming interfaces, integration contracts, and component boundaries, ensuring interoperability and backward compatibility across products.
  • Guide architectural and technical decisions while balancing performance, scalability, security, reliability, and maintainability.
  • Drive software quality through code reviews, automated testing, continuous integration and continuous delivery practices, and engineering standards.
  • Lead troubleshooting, root cause analysis, and resolution of complex product, integration, and customer issues.
  • Contribute to safety, cybersecurity, and risk management activities, including vulnerability remediation and technical documentation.
  • Collaborate with architects, product teams, and engineering leaders to manage technical priorities, dependencies, and delivery plans.
  • Mentor engineers and help elevate technical expertise, engineering practices, and software quality across the organisation.
Desired Qualifications
  • Experience working within healthcare, medical technology, or other regulated environments.
  • Knowledge of PostgreSQL, GitOps, infrastructure automation, and scripting.
  • Experience contributing to secure software development, observability, and cybersecurity practices.

About the company

Elekta specializes in precision radiation medicine, delivering devices and software that help clinicians treat cancer and brain disorders. Its core products are radiation therapy equipment (such as linear accelerators and advanced radiosurgery platforms) and treatment-planning and clinical workflow software. These tools work together: the hardware delivers targeted ionizing radiation to tumors while imaging and planning software optimize dose exactly where it is needed, then guide clinicians through the treatment workflow. Elekta differentiates itself by offering an integrated hardware-software ecosystem with a global installed base, a focus on reaching underserved markets, and ongoing services to support clinicians and facilities. The company's goal is to improve patient outcomes by expanding access to high-quality radiation therapy and growing its installed base around the world.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Stockholms kommun, Sweden

Founded

1972

Get referred to Elekta

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 EIB financing supplies €100 million for R&D through 2029.
  • Unity Pro launched at ASTRO 2026, adding AI contouring, GPU planning, and remote collaboration.
  • China and U.S. order growth improved in 2026, supporting Elekta’s recovery into 2027.

What critics are saying

  • Elekta cut 450 jobs in 2026; execution failures can destroy promised SEK500 million savings.
  • Second-quarter 2025/26 cancellations of SEK2,197 million expose order-quality problems and backlog fragility.
  • Siemens Healthineers and Varian dominate scale; missed product cycles would shrink Elekta into irrelevance.

What makes Elekta unique

  • Elekta Unity and Evo anchor MRI-guided, adaptive radiation unavailable from most rivals.
  • Its installed base spans 120 countries, giving hospitals workflows, service, and upgrades.
  • September 2026 ASTRO data strengthen Elekta’s clinical credibility in pancreatic cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Company Match
  • Paid Vacation
  • Hybrid Work Options
  • Wellness Program
  • Tuition Reimbursement

Growth & Insights and Company News

6 month growth

0%

1 year growth

2%

2 year growth

3%
AD HOC NEWS
Oct 18th, 2026
Marshall Wace becomes public short seller in Elekta stock.

Marshall Wace becomes public short seller in Elekta stock. Published on 10/18/2026 at 12:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Marshall Wace became a public short seller in Elekta on October 16, 2026. Elekta stock has a November 25 report date and SEK 3.54 billion in Q1 revenue. Short interest and operating signals. * Marshall Wace became a public short seller in Elekta on October 16, 2026. * Elekta generated SEK 3.54 billion in first-quarter revenue for fiscal 2027. * Elekta scheduled its second-quarter report for November 25, 2026. Elekta (ISIN SE0000163628) had one newly listed public short seller, Marshall Wace, on October 16, 2026, according to Affarsvarlden. The market event arrives while the company prepares to report second-quarter results on November 25, 2026. Discover more Find Cancer Care Source Med Gear Start Investing Affarsvarlden lists first-quarter fiscal 2027 revenue at SEK 3.54 billion and operating profit at SEK 395 million. First-quarter net income was SEK 261 million, while the operating margin reached 11.20 percent. Three dated Elekta developments. On September 27, 2026, Elekta announced an expanded adaptive radiotherapy portfolio covering CT, MR, radiosurgery and brachytherapy through Elekta. On September 28, 2026, a company study covering 123 pancreatic cancer patients reported overall survival of 37.40 percent at two years. On October 16, 2026, Marshall Wace was listed as one new public short seller in Elekta, according to Affarsvarlden. What does the next report test? The November 25 report will put the first-quarter figures into a broader trend. Revenue of SEK 3.54 billion was lower than the prior quarter's SEK 4.76 billion, while net income improved from a loss of SEK 866 million in the fourth quarter to SEK 261 million in the first quarter, based on the financial table published by Affarsvarlden. That comparison makes the next report important for judging whether the improved profit profile can continue. Dates for the next reports. Elekta lists November 25, 2026 for the second-quarter report. The following quarterly report is scheduled for February 25, 2027, according to the company calendar. Short interest meets operating data. The latest operating figures combine an 11.20 percent margin with SEK 3.54 billion in first-quarter revenue, while the October 16 short-selling disclosure adds a separate market signal. Elekta stock facts. * Company: Elekta AB (publ) * ISIN: SE0000163628 * Ticker: EKTA-B.ST * Primary exchange: Nasdaq Stockholm * Sector / Industry: Healthcare / Medical Devices Discover more Invest in Stocks Compare Brokers Sponsored Ad Elekta stock: new analysis - 24 October. Fresh Elekta information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | SE0000163628 | ELEKTA | boerse | 70353007 | bgmi

MarketScreener
Sep 29th, 2026
Elekta presents study at ASTRO 2026 showing promising long-term results.

Elekta presents study at ASTRO 2026 showing promising long-term results. Published on 09/29/2026 at 01:23 am EDT Finwire - Translated by Marketscreener - See original Medical technology company Elekta is highlighting new study data presented at ASTRO 2026 showing promising long-term results for patients with localized pancreatic cancer who were not candidates for surgery. The study at Memorial Sloan Kettering Cancer Center included 123 patients who were treated with high-dose MR-guided adaptive radiation therapy using Elekta Unity between May 2020 and December 2024. After a median follow-up of just over two years, overall survival was 37.4 percent at two years and 26.3 percent at three years. The proportion of patients without local progression was 76.8 percent at both two and three years. The researchers believe the results warrant further evaluation of the treatment strategy. Elekta is also continuing the development of Unity through Unity Pro, which includes AI-assisted contouring, GPU-accelerated planning and remote collaboration capabilities. (C) Finwire - 2026

Anderson Publishing, Ltd.
Sep 27th, 2026
Elekta announces adaptive radiotherapy portfolio with advanced capabilities at ASTRO 2026.

Elekta announces adaptive radiotherapy portfolio with advanced capabilities at ASTRO 2026. September 27, 2026 · News Release Elekta has revealed the expansion of its adaptive radiotherapy portfolio to include new functionalities across CT, MR, radiosurgery, and brachytherapy modalities. Unveiled at the ASTRO annual meeting, these advancements aim to integrate adaptive treatment options into routine clinical practice, offering more tailored and efficient patient care. The company's suite of adaptive solutions now extends to Elekta Unity for MR-guided radiotherapy, Elekta Evo for CT-guided online adaptive radiotherapy, and Leksell Gamma Knife Esprit for adaptive radiosurgery. Recently, Elekta introduced online adaptive capabilities for Elekta Harmony, a CT-Linac platform, and real-time adaptive planning for prostate brachytherapy with Elekta Prostate Guideway. Elekta Harmony's enhanced feature set, supported by Elekta ONE Online software, helps assess patient anatomy during treatment sessions and enables adaptive treatment-plan changes as needed. Designed for operational efficiency, Harmony provides streamlined workflows and automation to support continuous treatment delivery, even in high-volume settings. Chirag Shah, MD, Chair of the Department of Radiation Oncology at Allegheny Health Network, emphasized, "For adaptive radiotherapy to reach more patients, it has to fit into daily clinical practice. Different patients and disease sites need different approaches, and the workflows have to be practical and efficient for our team and clinically appropriate for the patient. Having adaptive options across Elekta's portfolio helps us deliver the same high-quality care across our network." Furthermore, Elekta Prostate Guideway introduces adaptive workflows for high-dose-rate (HDR) prostate brachytherapy. This solution integrates imaging, planning, and treatment adaptation within a single-room setup, featuring continuous dose recalculation and real-time plan updates that accommodate anatomical changes and needle shifts during the procedure. The integration of diagnostic MRI and biopsy data into the live treatment workflow, combined with instant visual feedback, supports well-informed target and treatment planning decisions. John Lapré, Elekta's Chief Business Line Officer for Brachytherapy Solutions, highlighted the importance of timely information in such treatments: "In a dynamic interventional procedure like prostate brachytherapy, having the right information at the right time can make a meaningful difference. When clinicians can continuously see the impact of changes and receive clear guidance, they can adapt treatment with greater confidence." These developments extend Elekta's adaptive offerings across multiple treatment modalities, providing clinicians the flexibility to choose the most appropriate imaging and workflow solutions based on patient needs and clinical circumstances. It is important to note that the regulatory status of some products may vary by region. The Prostate Guideway is still pre-commercial and awaiting FDA 510(k) clearance and EU CE marking. More in vendor News. September 29, 2026 September 28, 2026 September 22, 2026

Definite Article Media Limited
Sep 15th, 2026
HCA expands radiotherapy capabilities with MR Linac launch.

HCA expands radiotherapy capabilities with MR Linac launch. HCA Healthcare UK (HCA UK) has expanded its radiotherapy capabilities with the introduction of the Elekta Unity MR-Linac at The Harley Street Clinic, bringing personalised radiotherapy treatment to patients and furthering its complex cancer care offering. The MR-Linac combines a high-resolution MRI scanner with a linear accelerator, enabling clinicians to visualise tumours in real time while delivering radiotherapy. This approach, known as MR-guided and adaptive radiotherapy, allows treatment to be precisely targeted, even as tumours move or change shape during a treatment session. HCA explains the technology is particularly beneficial for cancers in areas of the body that are subject to movement during a treatment, such as prostate and central lung tumours. By continuously tracking tumour motion and adapting treatment accordingly, clinicians can deliver higher radiation doses with increased accuracy, HCA said, adding this may reduce the number of treatment sessions required for some patients while protecting surrounding healthy tissue. This acquisition of this image-guided radiotherapy represents a significant investment of £15m for HCA UK and marks the organisation's first MR-Linac system globally. The Harley Street Clinic becomes one of only a small number of providers in London to offer this advanced form of radiotherapy. Treatment will be delivered by HCA UK's multi-disciplinary cancer team, including consultant clinical oncologists, physicists, dosimetrists and radiographers, who work together on treatment planning and delivery. The service will be led by dedicated MR-Linac consultant, Dr Elena Moreno Olmedo, an expert in MR-guided radiotherapy. Dr Moreno Olmedo will oversee treatment sessions, working closely with the wider team to adapt each patient's radiotherapy plan in real time to ensure optimal precision. The introduction of the technology coincides with HCA UK joining the international Elekta MR-Linac Consortium, a global collaboration of centres focused on advancing evidence-based use of MR-guided radiotherapy. The consortium aims to optimise treatment approaches, improve tumour control and survival outcomes, and enhance patient quality of life through ongoing research and shared clinical expertise. Dr John Conibear, clinical oncologist and radiotherapy lead clinician at HCA UK, said: "MR-guided radiotherapy represents a significant advancement in how Healthcare & Protection deliver precision cancer treatment. "The ability to see and respond to tumour motion in real time allows Healthcare & Protection to treat with greater accuracy and confidence, particularly for tumours that have traditionally been challenging to target. "Ultimately, this means we can deliver highly personalised care with the potential for improved outcomes and fewer treatment sessions for patients." William Pressley, CEO at The Harley Street Clinic, added: "Healthcare & Protection is proud to be one of the first independent hospitals in London to offer advanced radiotherapy with the use of the MR-Linac at The Harley Street Clinic. "The introduction of this technology reflects its continued investment in advanced cancer care and its commitment to providing patients with access to the latest treatment innovations. "This technology enables our expert teams to deliver highly precise, adaptive radiotherapy, reinforcing our position as a leading centre for complex cancer treatment."

Göteborgs-Posten
Aug 29th, 2026
Elekta secures $112M EIB loan for advanced cancer treatment research

Stockholm-based medical technology company Elekta has secured a loan of SEK 1.1 billion from the European Investment Bank to advance cancer treatment development. The funding will support research into radiation therapy and radiosurgery for various cancers and neurological diseases, including treatment software development. CFO Klara Eiritz said the financing provides flexibility to execute the company's long-term strategy whilst investing in innovations that improve treatment outcomes and patient experience. Most research will be conducted in Sweden and the Netherlands. The EIB loan covers up to half of the total investment costs.